Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 57, Issue 1, 2016, Pages 161-166

  Higashi, Morihiro ^a   Tokuhira, Michihide ^a   Fujino, Satoshi ^a   Yamashita, Takahisa ^a   Abe, Keiko ^a   Arai, Eiichi ^a   Kizaki, Masahiro ^a   Tamaru, Jun Ichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diffuse large B cell lymphoma; HLA DR; tumor microenvironment

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; SOLUBLE INTERLEUKIN 2 RECEPTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADULT; ADVERSE OUTCOME; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADOLESCENT; CANCER GRADING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; FEMALE; GENE EXPRESSION; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84954242834     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1038708     Document Type: Article

References (31)

1. Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011;58:69-80.
2. Eng C. Microenvironmental protection in diffuse large-B-cell lymphoma. N Engl J Med 2008;359:2379-2381.
3. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
5. Stein HW, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. Pp 233-237.
6. Hanzawa K, Momose S, Higashi M, et al. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk Lymphoma 2010;51:2054-2062.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
9. Mikata A, Suzuki H, Ohkawa H. Immunohistochemical studies on B cell lymphomas with special reference to T cell infiltration and significance as a prognositic factor. Pathol Int 1988;38:47-58.
10. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251-4258.
11. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812.
12. Bernd HW, Ziepert M, Thorns C, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma-analyses of cases from two prospective randomized clinical trials. Haematologica 2009;94:1569-1580.
13. Lippman SM, Miller TP, Spier CM, et al. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988;72:436-441.
14. Miller TP, Lippman SM, Spier CM, et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988;82:370-372.
15. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-728.
16. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
17. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-282.
18. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013;48:452-458.
19. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569-3577.
20. Lokesh KN, Sathyanarayanan V, Kuntegowdanahalli CL, et al. Primary diffuse large B-Cell lymphoma of testis: a single centre experience and review of literature. Urol Ann 2014;6:231-234.
21. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-5912.
22. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433.
23. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:e218-228.
24. Toellner KM, Luther SA, Sze DM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med 1998;187:1193-1204.
25. Mantovani A, Allavena P, Sozzani S, et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004;14:155-160.
26. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007;19:217-223.
27. Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247-256.
28. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3 ? regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
29. Glowala-Kosinska M, Chwieduk A, Nieckula J, et al. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol 2013;91:122-128.
30. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 1057-1061.
31. Martorelli D, Muraro E, Merlo A, et al. Role of CD4 ? cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 2010;29:371-402.